okyo pharma corp - OKYO

OKYO

Close Chg Chg %
1.57 -0.04 -2.55%

Pre-Market

1.53

-0.04 (2.55%)

Volume: 275.71K

Last Updated:

Sep 8, 2026, 4:00 PM EDT

Company Overview: okyo pharma corp - OKYO

OKYO Key Data

Open

$1.56

Day Range

1.40 - 1.59

52 Week Range

1.34 - 3.20

Market Cap

N/A

Shares Outstanding

NaN

Public Float

35.64M

Beta

-0.03

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

N/A

Yield

N/A

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

71.34K

 

OKYO Performance

1 Week
 
-2.55%
 
1 Month
 
2.68%
 
3 Months
 
0.66%
 
1 Year
 
-28.84%
 
5 Years
 
N/A
 

OKYO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About okyo pharma corp - OKYO

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO At a Glance

OKYO Pharma Ltd.
35a Albemarle Street
London, Greater London W1S 4JE
Phone 44-20-7495-2379 Revenue 0.00
Industry Biotechnology Net Income -8,949,657.00
Sector Health Technology Employees N/A
Fiscal Year-end 03 / 2027
View SEC Filings

OKYO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 6.85
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.30
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

OKYO Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

OKYO Liquidity

Current Ratio 2.427
Quick Ratio 2.427
Cash Ratio 2.383

OKYO Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -72.603
Return on Equity -263.784
Return on Total Capital -72.554
Return on Invested Capital -263.784

OKYO Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Okyo Pharma Corp - OKYO

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
3.80K 3.87K 2.56K 1.82K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.80K 3.87K 2.56K 1.82K
Depreciation
3.80K 3.87K 2.56K 1.82K
Amortization of Intangibles
- - - -
-
COGS Growth
+56.70% +1.82% -33.70% -28.99%
Gross Income
(3.80K) (3.87K) (2.56K) (1.82K)
Gross Income Growth
-56.70% -1.82% +33.70% +28.99%
Gross Profit Margin
- - - -
-
2023 2024 2025 2026 5-year trend
SG&A Expense
13.08M 15.69M 7.19M 9.20M
Research & Development
6.34M 8.24M 2.25M 1.81M
Other SG&A
6.75M 7.45M 4.93M 7.39M
SGA Growth
+110.04% +19.93% -54.20% +28.00%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(13.09M) (15.69M) (7.19M) (9.20M)
Non Operating Income/Expense
(99.93K) (55.18K) 102.45K 732.85K
Non-Operating Interest Income
- - 5.47K 32.10K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
96.69K 1.05M 883.65K 474.22K
Interest Expense Growth
- +989.40% -16.11% -46.33%
Gross Interest Expense
96.69K 1.05M 883.65K 474.22K
Interest Capitalized
- - - -
-
Pretax Income
(13.28M) (16.80M) (7.97M) (8.94M)
Pretax Income Growth
-113.64% -26.49% +52.57% -12.19%
Pretax Margin
- - - -
-
Income Tax
(12.20K) 22.42K (3.26M) 7.99K
Income Tax - Current - Domestic
- 22.42K (3.26M) 7.99K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(13.27M) (16.83M) (4.71M) (8.95M)
Minority Interest Expense
- - - -
-
Net Income
(13.27M) (16.83M) (4.71M) (8.95M)
Net Income Growth
-144.35% -26.78% +72.03% -90.16%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(13.27M) (16.83M) (4.71M) (8.95M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(13.27M) (16.83M) (4.71M) (8.95M)
EPS (Basic)
-0.5963 -0.5734 -0.1192 -0.2396
EPS (Basic) Growth
-10,741.82% +3.84% +79.21% -101.01%
Basic Shares Outstanding
22.26M 29.34M 39.49M 37.36M
EPS (Diluted)
-0.5963 -0.5734 -0.1192 -0.2396
EPS (Diluted) Growth
-10,741.82% +3.84% +79.21% -101.01%
Diluted Shares Outstanding
22.26M 29.34M 39.49M 37.36M
EBITDA
(13.08M) (15.69M) (7.19M) (9.20M)
EBITDA Growth
-110.04% -19.93% +54.20% -28.00%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 8.333
Number of Ratings 3 Current Quarters Estimate -0.04
FY Report Date 09 / 2026 Current Year's Estimate -0.135
Last Quarter’s Earnings -0.03 Median PE on CY Estimate N/A
Year Ago Earnings -0.17 Next Fiscal Year Estimate -0.405
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 2 2
Mean Estimate -0.04 -0.04 -0.14 -0.41
High Estimates -0.04 -0.04 -0.12 -0.15
Low Estimate -0.04 -0.04 -0.15 -0.66
Coefficient of Variance N/A N/A -15.71 -89.04

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Okyo Pharma Corp in the News